NovaBay Launches Clinical Study For Non-Antibiotic Treatment Of Impetigo, One Of The Most Common Skin Infections
Links shared publicly online about this topic.
- 1,757total visits
NovaBay Launches Clinical Study For Non-Antibiotic Treatment Of Impetigo, One Of The Most Common Skin Infections
NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and funga
View full resource at medicalnewstoday.com
Tags: Skin, Impetigo, Infection, Pharma
Most Recently Shared on September 11, 2009 at 1:12 pm By:
NovaBay Launches Clinical Study For Non-Antibiotic Treatment Of Impetigo, One Of The Most Common Skin Infections.. http://bit.ly/e81n4
Advertisement
